1-(hydroxy(phenyl)methyl)cyclopropanecarboxylic acid | 108546-78-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 1-(hydroxy(phenyl)methyl)cyclopropanecarboxylic acid
• 英文别名: 1-[hydroxy(phenyl)methyl]cyclopropane-1-carboxylic acid
• CAS: 108546-78-7
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: UAWOCMUARRUCHU-UHFFFAOYSA-N

物化性质

• 熔点：
  92.0-93.2 °C
• 沸点：
  374.6±15.0 °C(Predicted)
• 密度：
  1.368±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-苯甲酰基环丙烷-1-羧酸 在 sodium amalgam 作用下， 生成 1-(hydroxy(phenyl)methyl)cyclopropanecarboxylic acid
  参考文献：
  名称：

  Marshall; Perkin, Journal of the Chemical Society, 1891, vol. 59, p. 887

  摘要：

  DOI：

文献信息

• Generation and Reactions of Lithiated<i>tert</i>-Butyl and 2,6-Di(<i>tert</i>-butyl)-4-methylphenyl Cyclopropanecarboxylates
  作者：Robert Häner、Thomas Maetzke、Dieter Seebach

  DOI：10.1002/hlca.19860690720

  日期：1986.10.29

  tert-Butyl and 2,6-di(tert-butyl)-4-methylphenyl (BHT) cyclopropanecarboxylates (4, 6, 24, 25) are lithiated with LiN(i-Pr)2 and t-BuLi, respectively. Reactions with alkyl halides, aldehydes, acyl chlorides, and heteroelectrophiles give α-substituted BHT esters which can be cleaved (t-BuOK/H2O/THF) to the corresponding carboxylic acids or reduced (LiAlH4/THF) to the cyclopropanemethanols.

  叔丁基和2,6-二（叔丁基）-4-甲基苯基（BHT）环丙烷羧酸酯（4，6，24，25）的与锂化的LiN（I-PR）2和吨分别正丁基锂。与烷基卤化物，醛，酰氯和杂亲电试剂的反应得到α-取代的BHT酯，其可以被裂解（t- BuOK / H 2 O / THF）成相应的羧酸或被还原（LiAlH 4 / THF）成环丙烷甲醇。
• [EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015005901A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20130183269A1

  公开（公告）日：2013-07-18

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：BRISTOL-MAYERS SQUIBB COMPANY

  公开号：US20160199355A1

  公开（公告）日：2016-07-14

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合、包含这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• Hepatitis C virus inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US09326973B2

  公开（公告）日：2016-05-03

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包含这种组合的组合物，以及抑制NS5A蛋白功能的方法。